Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Rating of "Buy" by Analysts

Key Points

• Analysts maintain a consensus “Buy” rating on Perspective Therapeutics, with eight buy ratings, one strong buy, and one hold among 10 analysts. The average 12-month price target is $11.50.
• Recent analyst actions were mixed: Bank of America downgraded its target to $5 and kept a neutral rating, while Piper Sandler reduced its target to $14 but maintained an overweight rating; BMO Capital Markets set an $11 outperform target.
• CATX opened at $2.81, below its 50-day and 200-day moving averages. The company reported a quarterly loss of $0.22 per share, better than the expected $0.25 loss, while institutional investors own 54.66% of its stock.

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been assigned an average rating of "Buy" from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.50.

CATX has been the subject of a number of research reports. Bank of America cut their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, August 14th. Piper Sandler lowered their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. BTIG Research restated a "buy" rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Finally, BMO Capital Markets set a $11.00 price objective on shares of Perspective Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, August 18th.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $2.81 on Friday. The stock's fifty day moving average price is $3.09 and its two-hundred day moving average price is $3.74. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%.The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. As a group, analysts forecast that Perspective Therapeutics will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CATX. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock worth $29,000 after purchasing an additional 5,475 shares during the last quarter. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics in the 4th quarter worth about $28,000. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $31,000. Abel Hall LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at about $49,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $35,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.